


AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (currently amended) A compound of Formula (I)-compounds



in which

the various ~~R1, R2, R3 and R4~~ R₁, R₂, R₃ and R₄, which can be the same or different, are H, OH, OPO₃H₂ or OCH₂OPO₃H₂ and their disodium salt, OMe, OCH₂O, NO₂NO₂, F, Cl, or Br;


~~-R1-R2-~~ -R₁-R₂- can also be together: ~~-CR8=CR9-X-~~ -CR₈=CR₉-X-;

~~-R1-R2-~~ can also be together: OCH₂O;

~~-R2-R3-~~ can also be together: OCH₂O;

~~-R3-R4-~~ can also be together: OCH₂O;

Y is a group selected from




w : *cis o trans*

~~R5 and R6~~ R₅ and R₆, which can be the same or different, are H or halogen;

~~R7 is H, OMe, SO₂Ph;~~

Ar is a group selected from:



~~R₈, R₉ and R₁₀~~ R₈, R₉ and R₁₀, which can be the same or different, are H, OH, OPO_3H_2 , OPO_3H_2 or $\text{OCH}_2\text{OPO}_3\text{H}_2$, $\text{OCH}_2\text{OPO}_3\text{H}_2$ and their disodium salt, OR_{11} , OCH_2O , NH_2 , NHR_{11} , NO_2 , alkyl (C_1 - C_4), C_6H_5 , $\text{C}_5\text{H}_4\text{NOR}_{11}$, OCH_2O , NH_2 , NHR_{11} , NO_2 , alkyl (C_1 - C_4), C_6H_5 , $\text{C}_5\text{H}_4\text{N}$ or halogen;

~~R₁₁ is C₁-C₄~~ R₁₁ is C₁-C₄ alkyl or acyl, aminoacids residue;

X is O, S, N, ~~NR₁₂~~ and;

~~R₁₂ is H, CH₃, CH₂Ph;~~

Z is CH₂, N;

with the proviso that the formula (I) compound is not combretastatin A-1, combretastatin A-2, combretastatin A-4, and their disodium phosphates derivatives and with the exclusion of the following compounds:

~~2-phenyl 6-*trans*-styryl benzo[b]furan;~~

~~2,3-diphenyl 6-*trans*-styryl benzo[b]furan;~~

~~2-phenyl 6-(4-methoxy)-*trans*-styryl benzo[b]furan;~~

~~2-phenyl 6-(3,4-dimethoxy)-*trans*-styryl benzo[b]furan;~~

~~2-phenyl 6-(3,4,5-trimethoxy)-*trans*-styryl benzo[b]furan;~~

~~2-phenyl 6-(3,4-methylenedioxy)-*trans*-styryl benzo[b]furan;~~

~~2,3-diphenyl 6-(4-methoxy)-*trans*-styryl benzo[b]furan;~~

~~2-phenyl 5-*trans*-styryl benzo[b]thiophene;~~

~~2-phenyl-5-(4-methoxy)-trans-styryl-benzo[b]thiophene;~~

~~2-phenyl-5-(3,4-methylenedioxy)-trans-styryl-benzo[b]thiophene;~~

~~2-phenyl-6-trans-styryl-benzo[b]thiophene;~~

~~2-phenyl-6-(4-methoxy)-trans-styryl-benzo[b]thiophene;~~

~~2-phenyl-6-(4-chloro)-trans-styryl-benzo[b]thiophene;~~

~~Piceatannol;~~

~~1-(3-furanyl)-2-(3,4,5-trimethoxyphenyl)ethene;~~

~~1-(3-thiophenyl)-2-(3,4,5-trimethoxyphenyl)ethene;~~

~~1-(2-furanyl)-2-(3,4,5-trimethoxyphenyl)ethene;~~

~~and with the proviso that~~

~~—when R1 is hydrogen and R2–R4 are 3,4,5-trimethoxy, Y is a double bond, R5 and R6 are H,~~

~~Ar is phenyl, R8 and R9 are hydrogen, R10 is not methoxy;~~

~~—when R1 is hydrogen and R2–R4 are 3,4,5-trimethoxy, Y is a double bond, R5 and R6 are H,~~

~~Ar is phenyl, R8 is hydrogen, R9 is 2-chloro, R10 is not 4-methoxy;~~

~~—when R1 is hydrogen and R2–R4 are trimethoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, at least one of R8–R10 is not hydrogen;~~

~~—when R1 is hydrogen and R2–R4 are 3,4,5-trimethoxy, Y is a double bond, R5 and R6 are H,~~

~~Ar is phenyl, R8 and R9 are hydrogen, R10 is none of 4-chloro, 4-bromo, 4-nitro, 4-hydroxy, 4-acetyl, 4-ethoxy, 4-C1–C4 alkyl;~~

~~—when R1 is hydrogen and R2–R4 are 3,4,5-trimethoxy, Y is a double bond, R5 and R6 are H,~~

~~Ar is phenyl, R8 is hydrogen, R9 is 4-nitro or 4-amino, R10 is none of 3-chloro, 3-methoxy, 3-methyl;~~

~~—when R1 is hydrogen and R2–R4 are 3,4,5 trimethoxy, Y is a *cis* double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 3-nitro or 3-amino, R10 is none of 3-chloro, 3-methoxy, 3-methyl;~~

~~—when R1 is hydrogen and R2–R4 are 2,3,4 trimethoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8 and R9 are hydrogen, R10 is not 4-methoxy;~~

~~—when R1 is hydrogen and R2–R4 are 3,4,5 trimethoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, at least one of R8 is hydrogen, R9 is 3-methoxy, R10 is not 5-methoxy;~~

~~—when R1 is hydrogen and R2–R4 are 3,4,5 trimethoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8–R10 are not methoxy;~~

~~—when R1 and R2 are hydrogen and R3–R4 are 3,4 dimethoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8 and R9 are hydrogen, R10 is not 4-methoxy;~~

~~—when R1 and R2 are hydrogen and R3–R4 are 3,4 dimethoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9–R10 are not 3,5 dimethoxy;~~

~~—when R1 and R2 are hydrogen and R3–R4 are 3,4 dimethoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, at least one of R8–R10 is not hydrogen;~~

~~—when R1 and R2 are hydrogen and R3–R4 are 3,5 methoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8 and R9 are hydrogen, R10 is not 4-methoxy;~~

~~—when R1 and R2 are hydrogen and R3–R4 are 3,5 methoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8 and R9 are hydrogen, R10 is not 4-acetyl;~~

~~—when R1 is hydrogen and R2–R4 are 3,4,5 trimethoxy, Y is a double bond, R5 and R6 are H, Ar is not pyridyl;~~

~~when R1 is hydrogen and R2–R4 are 3,4,5 trimethoxy, Y is *cis* double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 3-amino, R10 is 4-NHR11, R11 is not the residue of serine;~~

~~—when R1 is hydrogen and R2–R4 are 3,4,5 trimethoxy, Y is *cis* double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 3-amino, R10 is not 4-methoxy;~~

~~—when R1 is hydrogen and R2–R4 are 3,4,5 trimethoxy, Y is *cis* double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 3-amino, R10 is not a 4-alkyloxy group having from 1 to 3 carbon atoms, or a 4-alkyl group having from 1 to 4 carbon atoms, or a halogen atom~~

~~—when R1 is hydrogen and R2–R3 are 3,4-methylenedioxy, R4 is 5-methoxy, Y is *cis* double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 3-amino, R10 is not 4-methoxy;~~

~~—when R1 is hydrogen and R2–R4 are 2,3,4 trimethoxy, Y is *cis* double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 3-amino, R10 is not 4-methoxy;~~

~~—when R1 is hydrogen and R2–R4 are 3,4,5 trimethoxy, Y is *cis* double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is NHR11, R11 is the residue of serine, R10 is not 4-methoxy;~~

~~—when R1 is hydrogen and R2–R3 are 3,4-methylenedioxy, R4 is 4-methoxy, Y is *cis* double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is NHR11, R11 is the residue of the aminoacid cysteine, glycine, phenylalanine, serine, triptophan, tyrosine, valine, R10 is not 4-methoxy;~~

~~—when R1 is hydrogen and R2–R3 are 3,4-methylenedioxy, R4 is 4-methoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is NO₂ or NH₂, R10 is not 4-methoxy;~~

~~—when R1 is hydrogen and R2–R4 are 3,4,5 trimethoxy, Y is *cis* double bond, R5 and R6 are H, Ar is phenyl, at least one of R8–R10 is not hydrogen;~~

~~—when R1 is hydrogen and R2–R4 are 3,4,5 trimethoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 4-methoxy, R10 is not 3-fluoro;~~

~~—when R1 is hydrogen and R2–R4 are 3,4,5 trimethoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 4-methyl, R10 is not 3-fluoro or 3-hydroxy;~~

~~—when R1 is hydrogen and R2-R4 are 3,4,5-trimethoxy, Y is *cis* double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 4-methoxy, R10 is not 3-methoxy;~~

~~—when R1 is hydrogen and R2-R4 are 3,4,5-trimethoxy, Y is *cis* double bond, R5 and R6 are H, Ar is phenyl, R8 is 3-fluoro, R9 is 4-methoxy, R10 is not 2- or 5-fluoro;~~

~~—when R1 is hydrogen and R2-R4 are 3,4,5-trimethoxy, Y is *cis* double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 4-methoxy, R10 is not 3-hydroxy or 3-amino;~~

~~—when R1 is hydrogen and R2-R4 are 3,4,5-trimethoxy, Y is *cis* double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 4-methoxy, R10 is not 3-fluoro or 3-bromo;~~

~~—when R1 is hydrogen and R2-R4 are 3,4,5-trimethoxy, Y is *cis* double bond, R5 and R6 are H, Ar is phenyl, R8 and R9 are hydrogen, R10 is not 4-hydroxy;~~

~~—when R1 is hydrogen and R2-R4 are 3,4,5-trimethoxy, Y is *cis* double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 3-methyl, R10 is not 4-methyl;~~

~~—when R1 is hydrogen and R2-R4 are 3,4,5-trimethoxy, Y is *cis* double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 4-methoxy, R10 is not 3-hydroxy;~~

~~—when R1-R2 are hydrogen and R3-R4 are 3,5-dihydroxy, Y is *trans* double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 is 3-hydroxy, R10 is not 5-hydroxy;~~

~~—when R1-R3 are hydrogen, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 and R10 are 3,4-dimethyl, and R4 is not 4-methoxy;~~

~~—when R1-R2 are hydrogen, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8 is hydrogen, R9 and R10 are 3,4-dimethyl, R4 is 4-methoxy, R3 is not 3-fluoro or 3-bromo or 3-nitro or 3-hydroxy;~~

~~—when R1-R2 are hydrogen, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8-R10 are 3,4,5-triethoxy, R4 is 4-methoxy, R3 is not 3-fluoro or 3-chloro or 3-bromo or 3-hydroxy;~~

~~—when R1-R2 are hydrogen, R4 is 4-methoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8-R9 are 4,5-dimethoxy, R10 is 3-hydroxy, R3 is not 3-fluoro or 3-hydroxy;~~


~~—when R1-R2 are hydrogen, R4 is 4-methoxy, Y is a double bond, R5 and R6 are H, Ar is phenyl, R8-R9 are 4,5-dimethoxy, R10 is 3-methoxy, R3 is not 3-fluoro;~~

~~—when R1 is hydrogen, R2-R4 are 3,4,5-trimethoxy, Y is a double bond, R5 and R6 are H, Ar is 2-naphthyl, at least one of R8-R10 is not hydrogen;~~

~~—when R1 and R2 are hydrogen, R3 is 3-hydroxy, R4 is 4-methoxy, Y is a double bond, R5 and R6 are H, Ar is 2-naphthyl, at least one of R8-R10 is not hydrogen;~~

~~—when R1 is hydrogen, R2-R4 are 3,4,5-trimethoxy,~~

~~Y is~~



~~Ar is indolyl, wherein at least one of R8-R10 is different from hydrogen;~~

their enantiomers, diastereoisomers, the respective mixtures and their pharmaceutically acceptable salts.

2. (currently amended) ~~Compound~~ A compound according to claim 1, selected from the group consisting of:

~~2-methoxy-5-[3-methoxy-5-(3,4,5-trimethoxy-phenyl)-4,5-dihydro-4-isoxazolyl]-phenol;~~

~~2-methoxy-5-[3-methoxy-4-(3,4,5-trimethoxy-phenyl)-4,5-dihydro-5-isoxazolyl]-phenol;~~

~~5-[3-benzenesulphonyl-4-(3,4,5-trimethoxy-phenyl)-4,5-dihydro-4-isoxazolyl]-2-methoxy-phenol;~~

~~5-[3-benzenesulphonyl-5-(3,4,5-trimethoxy-phenyl)-4,5-dihydro-5-isoxazolyl]-2-methoxy-phenol;~~

~~2-methoxy-5-[3-(3,4,5-trimethoxy-phenyl)-4,5-dihydro-5-isoxazolyl]-phenol;~~

~~2-methoxy-5-[5-(3,4,5-trimethoxy-phenyl)-4,5-dihydro-3-isoxazolyl]-phenol;~~

~~2-methoxy-5-[5-(3,4,5-trimethoxy-phenyl)-3-isoxazole]-phenol;~~

~~cis-6-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-benzo[b]thiophen-4-ol;~~

~~trans-6-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-benzo[b]thiophen-4-ol;~~

~~cis-4-methoxy-6-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-benzo[b]thiophene;~~

~~trans-4-methoxy-6-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-benzo[b]thiophene;~~

~~cis-6-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-benzofuran-4-ol;~~

~~trans-6-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-benzofuran-4-ol;~~

~~cis-4-methoxy-6-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-benzofuran;~~

~~trans-4-methoxy-6-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-benzofuran;~~

~~cis-5-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-benzo[b]thiophen-7-ol;~~

~~trans-5-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-benzo[b]thiophen-7-ol;~~

~~cis-5-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-benzofuran-7-ol;~~

~~trans-5-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-benzofuran-7-ol;~~

~~cis-1-methoxy-3-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-naphthalene;~~

~~methoxy-3-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-naphthalene;~~

~~cis-7-methoxy-1-methyl-5-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-1H-indazole;~~

~~trans-7-methoxy-1-methyl-5-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-1H-indazole;~~

~~2-nitro-5-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-thiophene;~~

~~2-nitro-5-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-furan;~~

~~cis-3-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-naphthalen-1-ol;~~

~~trans-3-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-naphthalen-1-ol;~~

~~disodium 6[(Z)-2-(3,4,5-trimethoxy-phenyl)ethenyl]-1-benzo-thiophen-4-ol 4-O-phosphate;~~

~~disodium 6[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-1-benzo-furan-4-ol 4-O-phosphate;~~

~~6-[(Z)-2-(7-methoxy-1,3-benzodioxol-5-yl)vinyl]-1-benzothiophene-4-ol;~~

~~6-[(E)-2-(7-methoxy-1,3-benzodioxol-5-yl)vinyl]-1-benzothiophene-4-ol;~~

~~6-[(Z)-2-(3-methoxy-4,5-methylenedioxy-phenyl-1-yl)-vinyl]-1-benzofuran-4-ol;~~

~~6-[(E)-2-(3-methoxy-4,5-methylenedioxyphenyl-1-yl)-vinyl]-1-benzofuran-4-ol;~~

~~disodium 6-[(Z)-2-(3,4,5-trimethoxy-phenyl)ethenyl]-1-benzo-thiophen-4-ol 4-O-~~

~~methyloxyphosphate;~~

~~disodium 6-[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-1-benzo-furan-4-ol 4-O-~~

~~methyloxyphosphate;~~

~~6-[(Z)-2-(7-methoxy-1,3-benzodioxol-5-yl)vinyl]-1-benzothiophene-4-ol;~~

~~6-[(E)-2-(7-methoxy-1,3-benzodioxol-5-yl)vinyl]-1-benzothiophene-4-ol~~

~~6-[(Z)-2-(3-methoxy-4,5-methylenedioxy-phenyl-1-yl)-vinyl]-1-benzofuran-4-ol;~~

~~6-[(E)-2-(3-methoxy-4,5-methylenedioxy-phenyl-1-yl)-vinyl]-1-benzofuran-4-ol;~~

~~disodium 6[(Z)-2-(3,4,5-trimethoxy-phenyl)ethenyl]-1-benzo-thiophen-4-ol 4-O-~~

~~methyloxyphosphate;~~

~~disodium 6[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-1-benzo-furan-4-ol 4-O-~~

~~methyloxyphosphate;~~

~~6-[(Z)-2-(7-methoxy-1,3-benzodioxol-5-yl)vinyl]-1-benzothiophene-4-ol;~~

~~cis-2-Methoxy-5-[2-(4-methoxy-benzofuran-6-yl)-vinyl]-phenol;~~

~~cis-2-Methoxy-5-[2-(7-methoxy-benzofuran-5-yl)-vinyl]-phenol;~~

~~cis-2-Methoxy-5-[2-(4-methoxy-benzo[b]thiophen-6-yl)-vinyl]-phenol;~~

~~cis-6-[2-(3,5-dimethoxy-phenyl)-vinyl]-benzo[b]thiophen-4-ol;~~

cis-5-[2-(3,5-dimethoxy-phenyl)-vinyl]-benzofuran-7-ol; and

cis-6-[2-(3,5-dimethoxy-phenyl)-vinyl]-benzofuran-4-ol;

their enantiomers, diastereoisomers, the respective mixtures and their pharmaceutically acceptable salts.

3.-4. (canceled).

5. (withdrawn/currently amended) ~~Use according to claim 3 for the preparation of a medicament for the treatment of~~ A method of treating cancers that respond to cytotoxic activity comprising administering to a subject in need of same an effective amount of a compound of claim 1.

6. (withdrawn/currently amended) ~~[[Use]]~~ The method according to claim 5, in which said cancer is selected from the group consisting of sarcoma, carcinoma, carcinoid, bone cancer, neuroendocrine cancer, lymphoid leukaemia, myeloid leukaemia, monocytic leukaemia, megakaryocytic leukaemia, ~~[[or]]~~ and Hodgkin's disease.

7. (withdrawn/currently amended) ~~Use of compounds according to claim 1 for the preparation of a medicament for the treatment of~~ A method of treating diseases related to

abnormal angiogenesis comprising administering to a subject in need of same an effective amount of a compound of claim 1.


8. (withdrawn/currently amended) ~~[[Use]]~~The method according to claim 7, in which said disease is selected from the group consisting of arthritic disease, tumours responding to antiangiogenic activity, metastatic spread, diabetic retinopathy, psoriasis, chronic inflammation, and atherosclerosis.

9. (withdrawn/currently amended) ~~[[Use]]~~The method according to claim ~~[[4]]~~5, in which, in the treatment of tumours, said ~~medicament~~compound is combined with at least one other antitumour drug.

10. (withdrawn/currently amended) ~~[[Use]]~~The method according to claim 9, in which said antitumour drug is selected from the group consisting of alkylating agents; topoisomerase inhibitors; antitubulin agents; intercalating agents; antimetabolites; naturally occurring products such as Vinca alkaloids, epipodophyllotoxins, antibiotics, enzymes, taxanes and anticancer vaccines.

11. (previously presented) ~~Pharmaceutical~~A pharmaceutical composition containing as the active ingredient a compound according to claim 1 in a mixture with a pharmaceutically acceptable excipient or diluent.


12. (withdrawn) Use of the compound with the formula



in which

X is oxygen or sulphur, as an intermediate product for the preparation of compounds according to claim 1.


13. (withdrawn) Compound with the formula:



in which

X is oxygen or sulphur, R is methyl, or terbutyl-dimethylsilyl.

14. (withdrawn) Compound with the formula




in which

X is oxygen or sulphur, R is methyl, or terbutyl-dimethylsilyl.

R1 is formyl.


15. (withdrawn) Use of the compound with the formula



in which

X is oxygen or sulphur, as an intermediate product for the preparation of compounds according to claim 1.


16. (withdrawn) Compound with the formula



in which

X is oxygen or sulphur.

17. (withdrawn) Compound with the formula



in which

X is oxygen or sulphur.

18. (canceled).